Key Considerations for Policymakers-Iodized Salt as a Vehicle for Iron Fortification: Current Evidence, Challenges, and Knowledge Gaps.


Journal

The Journal of nutrition
ISSN: 1541-6100
Titre abrégé: J Nutr
Pays: United States
ID NLM: 0404243

Informations de publication

Date de publication:
15 02 2021
Historique:
received: 22 04 2020
revised: 27 05 2020
accepted: 04 11 2020
entrez: 14 2 2021
pubmed: 15 2 2021
medline: 26 8 2021
Statut: ppublish

Résumé

Could DFS help prevent iron deficiency and anemia? Studies in controlled settings (efficacy) demonstrate that double-fortified salt (DFS; iron added to iodized salt) reduces the prevalence of anemia and iron deficiency anemia. Studies in program settings (effectiveness) are limited and reported differing levels of DFS coverage, resulting in mixed evidence of impact on anemia. What iron formulations are available and how do they affect iodized salt? Ferrous sulfate and encapsulated ferrous fumarate (both with various enhancers and/or coating materials) are the main iron formulations currently in use for DFS. Adding iron to iodized salt may lead to adverse changes in the product, specifically discoloration and losses in iodine content. These changes are greatest when the iodized salt used in DFS production is of low quality (e.g., contain impurities, has high moisture, and is of large crystal size). DFS requires iodized salt of the highest quality and a high-quality iron formulation in order to minimize adverse sensory changes and iodine losses. Appropriate packaging of iodized salt is also important to prevent losses. What is known about the minimum requirements to manufacture DFS? DFS producers must use high-quality refined iodized salt meeting the minimum standards for DFS production (which is higher than standards for salt intended for iodization alone), and an iron formulation for which there are rigid quality-assurance measures to ensure consistent quality and blending techniques. The actual proportion of iodized salt meeting the stringent requirements necessary for DFS production is unclear, but likely to be low in many countries, especially those with fragmented salt industries and a low proportion of industrially produced salt. What are the financial implications of adding iron to iodized salt? As a result of higher input costs both for input salt and the iron compound, DFS is more expensive to produce than iodized salt and thus has a higher production cost. Various grades of iodized salt are produced and consumed in different sectors of the market. Experience in India indicates that, on average, producing DFS costs 31-40 US dollars/metric ton or 0.03-0.04 US dollars/kg more than high-quality refined iodized salt. The exact impact of this production-level cost difference on profit margins and consumer price is specific to the conditions of different salt markets. Factors such as transport costs, customary wholesale and retail mark-ups, and taxes all vary greatly and need to be assessed on a case by case basis. Is DFS in alignment with salt-reduction efforts? The WHO has long recognized that salt iodization is an important public health intervention to achieve optimal iodine nutrition and is compatible with salt-reduction goals. Fortification of salt (with any nutrient) should not be used to justify or encourage an increase in salt intake to the public. Any effort to expand salt fortification to other nutrients should be done in close consultation with WHO and those working on salt reduction. What has been the experience with DFS delivery under different platforms? To date, DFS has been introduced into the retail market and in social safety net (primarily in India) programs, but sensory changes in DFS have been raised as concerns. The higher price for DFS has limited expansion in the retail market. In social safety net programs where the cost of DFS is subsidized for beneficiaries, programs must consider long-term resourcing for sustainability. Overall: The optimal production and delivery of DFS are still under development, as many challenges need to be overcome. There is a beneficial impact on hemoglobin in efficacy trials. Thus, if those conditions can be replicated in programs or the technology can be adapted to better fit current production and delivery realities, DFS may provide an effective contribution in countries that need additional food-fortification vehicles to improve iron intake.

Identifiants

pubmed: 33582786
pii: S0022-3166(22)00472-2
doi: 10.1093/jn/nxaa377
pmc: PMC7882367
doi:

Substances chimiques

Iron Compounds 0
Iron, Dietary 0
Sodium Chloride, Dietary 0
iodized salt 0
Iodine 9679TC07X4

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

64S-73S

Investigateurs

Omar Dary (O)
Rafael Flores-Ayala (R)
Dipika Matthias (D)

Informations de copyright

Copyright © The Author(s) on behalf of the American Society for Nutrition 2021.

Références

Am J Clin Nutr. 2004 Oct;80(4):952-9
pubmed: 15447905
J Nutr. 2006 Jul;136(7):1814-20
pubmed: 16772442
Eur J Clin Nutr. 2009 Mar;63(3):437-45
pubmed: 18091768
Food Nutr Bull. 2007 Dec;28(4 Suppl):S524-39
pubmed: 18297891
Cochrane Database Syst Rev. 2020 Jul 17;7:CD011302
pubmed: 32677706
Cochrane Database Syst Rev. 2018 Dec 22;12:CD010187
pubmed: 30577080
J Nutr. 2021 Feb 15;151(Suppl 1):38S-46S
pubmed: 33582783
J Nutr. 2021 Feb 15;151(Suppl 1):47S-63S
pubmed: 33582784
BMJ Open. 2013 Dec 23;3(12):e003733
pubmed: 24366578
J Nutr. 2021 Feb 15;151(Suppl 1):3S-14S
pubmed: 33582781
J Nutr. 2021 Feb 15;151(Suppl 1):1S-2S
pubmed: 33582780
Matern Child Nutr. 2019 May;15 Suppl 3:e12773
pubmed: 31148400
Cochrane Database Syst Rev. 2019 Oct 25;2019(10):
pubmed: 31684687
J Nutr. 2021 Feb 15;151(Suppl 1):15S-28S
pubmed: 33582785
Am J Clin Nutr. 2003 Feb;77(2):425-32
pubmed: 12540404
J Nutr. 2021 Feb 15;151(Suppl 1):29S-37S
pubmed: 33582782
Indian J Med Res. 1998 Nov;108:203-11
pubmed: 9863276
Bull World Health Organ. 2014 Apr 1;92(4):231
pubmed: 24700987
Curr Dev Nutr. 2020 Aug 10;4(9):nzaa133
pubmed: 32885134
Food Nutr Bull. 2004 Sep;25(3):264-70
pubmed: 15460270
Blood. 2013 Apr 4;121(14):2607-17
pubmed: 23355536
Am J Clin Nutr. 2008 Nov;88(5):1378-87
pubmed: 18996875
Am J Clin Nutr. 2012 Aug;96(2):309-24
pubmed: 22760566
Cochrane Database Syst Rev. 2013 Apr 30;(4):CD004937
pubmed: 23633321

Auteurs

Adam Drewnowski (A)

Center for Public Health Nutrition, University of Washington, Seattle, WA, USA.

Greg S Garrett (GS)

ThinkWell, Geneva, Switzerland.
Global Alliance for Improved Nutrition (GAIN), Geneva, Switzerland.

Rishi Kansagra (R)

PureBond Ltd, London, United Kingdom.

Noor Khan (N)

Nutrition International, Ottawa, Canada.

Roland Kupka (R)

United Nations Children's Fund (UNICEF) Headquarters, New York, NY, USA.

Anura V Kurpad (AV)

Department of Physiology, St. John's Medical College, St. John's National Academy of Health Sciences, Bangalore, India.

Venkatesh Mannar (V)

Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, Canada.

Reynaldo Martorell (R)

Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA.

Michael B Zimmermann (MB)

Department of Health Science and Technology, Laboratory of Human Nutrition, Institute of Food Nutrition and Health, ETH Zurich, Zurich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH